Metabolic dysfunction-associated steatotic liver disease in adults
The DOI matches its Crossref record; 355 of the 355 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–355 of 355
De, A., Bhagat, N., Mehta, M., Taneja, S., & Duseja, A. K. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.031 · Cited by 165
Ferraioli, G., Barr, R. G., Berzigotti, A., Sporea, I., Wong, V. W., Reiberger, T., Karlas, T., Thiele, M. S., Cardoso, A. C., Ayonrinde, O. T., et al. (2024) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2024.03.014 · Cited by 165
Self-citationNoureddin, M., Charlton, M. R., Harrison, S. A., Bansal, M. B., Alkhouri, N., Loomba, R., Sanyal, A. J., & Rinella, M. E. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.003 · Cited by 165
Self-citationRinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.029 · Cited by 164 · cited 1×
“In the phase III trial of obeticholic acid for MASH, changes in NITs, such as liver stiffness measurement by VCTE, were associated with fibrosis regression, but thresholds have not been developed 215 .”
Alvarez-Sola, G., Uriarte, I., Latasa, M. U., Fernandez-Barrena, M. G., Urtasun, R., Elizalde, M., Barcena-Varela, M., Jiménez, M., Chang, H. C., Barbero, R., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312975 · Cited by 164
Brunt, E. M., Clouston, A. D., Goodman, Z., Guy, C., Kleiner, D. E., Lackner, C., Tiniakos, D. G., Wee, A., Yeh, M., Leow, W. Q., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.011 · Cited by 162
Self-citationAsian perspective on NAFLD-associated HCC
Yip, T. C.-F., Lee, H. W., Chan, W. K., Wong, G. L.-H., & Wong, V. W.-S. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.024 · Cited by 161
Self-citationDavid, K., Kowdley, K. V., Unalp, A., Kanwal, F., Brunt, E. M., & Schwimmer, J. B. (2009) · Hepatology · doi:10.1002/hep.22868 · Cited by 160
Paige, J. S., Bernstein, G. S., Heba, E., Costa, E. A. C., Fereirra, M., Wolfson, T., Gamst, A. C., Valasek, M. A., Lin, G. Y., Han, A., et al. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.16.16726 · Cited by 160
Self-citationTincopa, M. A., & Loomba, R. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00066-3 · Cited by 160
Self-citationBoursier, J., Guillaume, M., Leroy, V., Irlès, M., Roux, M., Lannes, A., Foucher, J., Zuberbuhler, F., Delabaudière, C., Barthelon, J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.020 · Cited by 157
Self-citationGorden, D. L., Ivanova, P. T., Myers, D. S., McIntyre, J. O., VanSaun, M. N., Wright, J. K., Matrisian, L. M., & Brown, H. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022775 · Cited by 155
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
Allen, A. M., Lazarus, J. V., & Younossi, Z. M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.026 · Cited by 155
Self-citationSimpson, R. F., Hermon, C., Liu, B., Green, J., Reeves, G. K., Beral, V., & Floud, S. (2019) · The Lancet Public Health · doi:10.1016/s2468-2667(18)30230-5 · Cited by 154
Defining comprehensive models of care for NAFLD
Lazarus, J. V., Anstee, Q. M., Hagström, H., Cusi, K. J., Cortez‐Pinto, H., Mark, H. E., Roden, M., Tsochatzis, E. A., Wong, V. W., Younossi, Z. M., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00477-7 · Cited by 152
Self-citationDietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD)
Alwahsh, S. M., & Gebhardt, R. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1892-7 · Cited by 150
A global research priority agenda to advance public health responses to fatty liver disease
Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Alazawi, W., Alkhouri, N., Alqahtani, S. A., Arrese, M. A., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.035 · Cited by 149
Self-citationRasouli, N., Raue, U., Miles, L. M., Lu, T., Di Gregorio, G. B., Elbein, S. C., & Kern, P. A. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00522.2004 · Cited by 148
Andersson, A., Kelly, M., Imajo, K., Nakajima, A., Fallowfield, J. A., Hirschfield, G., Pavlides, M., Sanyal, A. J., Noureddin, M., Banerjee, R., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.041 · Cited by 148
IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies
Mirea, A.-M., Tack, C. J., Chavakis, T., Joosten, L. A. B., & Toonen, E. J. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.005 · Cited by 144
Tan, D. J. H., Setiawan, V. W., Ng, C. H., Lim, W. H., Muthiah, M. D., Tan, E. X., Dan, Y. Y., Roberts, L. R., Loomba, R., & Huang, D. Q. (2023) · Hepatology · doi:10.1002/hep.32758 · Cited by 144
Self-citationSripongpun, P., Kim, W. R., Mannalithara, A., Charu, V., Vidovszky, A. A., Asch, S. M., Desai, M., Kim, S. H., & Kwong, A. J. (2022) · Hepatology · doi:10.1002/hep.32545 · Cited by 143
Ajmera, V., Kim, B. K., Yang, K., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idilman, R., Gumussoy, M., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.06.073 · Cited by 138
Self-citationSanyal, A. J., Ratziu, V., Loomba, R., Anstee, Q. M., Kowdley, K. V., Rinella, M. E., Sheikh, M. Y., Trotter, J. F., Knapple, W., Lawitz, E. J., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.014 · Cited by 137
Self-citationHepatic glucose metabolism in the steatotic liver
Scoditti, E., Sabatini, S., Carli, F., & Gastaldelli, A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00888-8 · Cited by 134
Golovaty, I., Tien, P. C., Price, J. C., Sheira, L., Seligman, H., & Weiser, S. D. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxz212 · Cited by 134
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis
Tavaglione, F., Jamialahmadi, O., Vincentis, A. D., Qadri, S. U., Mowlaei, M. E., Mancina, R. M., Ciociola, E., Carotti, S., Perrone, G., Bruni, V., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.03.044 · Cited by 133
Self-citationBreakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
Sanyal, A. J., Shankar, S. S., Yates, K. P., Bolognese, J., Daly, E., Dehn, C. A., Neuschwander-Tetri, B., Kowdley, K., Vuppalanchi, R., Behling, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02539-6 · Cited by 131
Self-citationToh, J. Z. K., Pan, X.-H., Tay, P. W. L., Ng, C. H., Yong, J. N., Xiao, J., Koh, J. H., Tan, E. Y., Tan, E. X. X., Dan, Y. Y., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.09.021 · Cited by 130 · cited 1×
“Regardless, nearly 50% of individuals with MASLD have coronary heart disease and more than a third have carotid artery atherosclerosis 72,73 .”
Germline Mutations in CIDEB and Protection against Liver Disease
Verweij, N., Haas, M. E., Nielsen, J. B., Sosina, O. A., Kim, M., Akbari, P., De, T., Hindy, G., Bovijn, J., Persaud, T., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117872 · Cited by 127
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Tincopa, M. A., Anstee, Q. M., & Loomba, R. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.011 · Cited by 126
Self-citationGlobal survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Younossi, Z. M., Alqahtani, S. A., Alswat, K., Yilmaz, Y. N., Keklikkıran, Ç., Funuyet‐Salas, J., Romero‐Gómez, M., Fan, J., Zheng, M., El‐Kassas, M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.11.004 · Cited by 125
Self-citationSubichin, M., Clanton, J., Makuszewski, M., Bohon, A., Zografakis, J. G., & Dan, A. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2014.06.015 · Cited by 124 · cited 1×
“The prevalence of MASLD and MASH is high in people with morbid obesity, with one study of 1,000 patients who underwent liver biopsies before weight loss surgery reporting that 66% had steatosis and 14% had MASH and/or fibrosis 249 .”
Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis
Loomba, R., Sanyal, A. J., Kowdley, K. V., Terrault, N., Chalasani, N. P., Abdelmalek, M. F., McCullough, A. J., Shringarpure, R., Ferguson, B., Lee, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.09.021 · Cited by 124 · cited 1×
“A secondary analysis of a randomized trial of obet-icholic acid in participants with MASH identified that a decline in ALT at week 24 by ≥17 U/l (ALT response) was associated with a histologic response 211 .”
Self-citationFrom NAFLD to MASLD: implications of the new nomenclature for preclinical and clinical research
Hsu, C. L., & Loomba, R. (2024) · Nature Metabolism · doi:10.1038/s42255-024-00985-1 · Cited by 123
Self-citationEslam, M., Mangia, A., Berg, T., Chan, H. L. Y., Irving, W. L., Dore, G. J., Abate, M. L., Bugianesi, E., Adams, L. A., Najim, M. A. M., et al. (2016) · Hepatology · doi:10.1002/hep.28475 · Cited by 122
Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design
Allen, A. M., Therneau, T. M., Ahmed, O. T., Gidener, T., Mara, K. C., Larson, J. J., Canning, R. E., Benson, J. T., & Kamath, P. S. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.004 · Cited by 121
Cholankeril, G., Kramer, J. R., Chu, J., Yu, X., Balakrishnan, M., Li, L., El-Serag, H. B., & Kanwal, F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.035 · Cited by 119 · cited 19×
“More than 30% of MASLD-related HCC occurs in people without cirrhosis 5 .”
InfluentialMachine learning enables new insights into genetic contributions to liver fat accumulation
Haas, M. E., Pirruccello, J. P., Friedman, S. N., Wang, M., Emdin, C. A., Ajmera, V. H., Simon, T. G., Homburger, J. R., Guo, X., Budoff, M., et al. (2021) · Cell Genomics · doi:10.1016/j.xgen.2021.100066 · Cited by 118
Self-citationConfirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD
Ratziu, V., Boursier, J., de Lédinghen, V., Anty, R., Costentin, C. E., & Bureau, C. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.017 · Cited by 117
Self-citationBarb, D., Kalavalapalli, S., Leiva, E. G., Bril, F., Huot-Marchand, P., Dzen, L., Rosenberg, J. T., Junien, J., Broqua, P., Rocha, A. O., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.045 · Cited by 116
Global epidemiology of lean non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Lu, F., Zheng, K. I., Rios, R. S., Targher, G., Byrne, C. D., & Zheng, M. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15156 · Cited by 115
Tang, A. S. P., Chan, K. E., Quek, J., Xiao, J., Tay, P. W. L., Teng, M. L. P., Lee, K. S., Lin, S. Y., Myint, M. Z., Tan, B. Y., et al. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0406 · Cited by 115
Self-citationRatziu, V., Hompesch, M., Petitjean, M., Serdjebi, C., Iyer, J. S., Parwani, A. V., Tai, D., Bugianesi, E., Cusi, K. J., Friedman, S. L., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.015 · Cited by 114
Self-citationCauses and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Konyn, P., Ahmed, A., & Kim, D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0351 · Cited by 113
Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327777 · Cited by 110 · cited 2×
“A study of four randomized trials of participants with biopsy-proven MASH with advanced fibrosis determined that a baseline liver stiffness measurement by VCTE of ≥30.7 kPa was strongly associated with liver-related outcomes 196 .”
InfluentialSelf-citationNogueira, J. P., & Cusi, K. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0013 · Cited by 110
Activation of the hepatic LDL receptor promoter by thyroid hormone.
Lopez, D., Abisambra Socarrás, J. F., Bedi, M., & Ness, G. C. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.001 · Cited by 109
Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease
Semmler, G., Yang, Z., Fritz, L., Köck, F., Hofer, B. S., Balcar, L., Hartl, L., Jachs, M., Stopfer, K., Schedlbauer, A., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.06.030 · Cited by 108
Treating NASH by targeting peroxisome proliferator-activated receptors
Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 108
Younossi, Z. M., Yilmaz, Y., Yu, M.-L., Wai-Sun Wong, V., Fernandez, M. C., Isakov, V. A., Duseja, A. K., Mendez-Sanchez, N., Eguchi, Y., Bugianesi, E., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.11.004 · Cited by 107
Loomba, R., Lawitz, E. J., Frias, J. P., Ortiz-Lasanta, G., Johansson, L., Franey, B. B., Morrow, L., Rosenstock, M., Hartsfield, C. L., Chen, C.-Y., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00347-8 · Cited by 106
Self-citationHIGUCHI, N., KATO, M., TANAKA, M., MIYAZAKI, M., TAKAO, S., KOHJIMA, M., KOTOH, K., ENJOJI, M., NAKAMUTA, M., & TAKAYANAGI, R. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.328 · Cited by 106
Kim, B. K., Tamaki, N., Imajo, K., Yoneda, M., Sutter, N., Jung, J., Lin, T., Tu, X. M., Bergstrom, J., Nguyen, K., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.020 · Cited by 106
Self-citationNatural history of NASH and HCC
Negro, F. (2020) · Liver International · doi:10.1111/liv.14362 · Cited by 104
Vespasiani‐Gentilucci, U., Carotti, S., Perrone, G., Mazzarelli, C., Galati, G., Onetti‐Muda, A., Picardi, A., & Morini, S. (2015) · Liver International · doi:10.1111/liv.12531 · Cited by 99
Simon, T. G., Patorno, E., & Schneeweiss, S. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.07.010 · Cited by 98
Tsofliou, F., Vlachos, D., Hughes, C., & Appleton, K. M. (2022) · Nutrients · doi:10.3390/nu14204314 · Cited by 98
Noureddin, M., Truong, E., Mayo, R., Martínez‐Arranz, I., Mincholé, I., Bañales, J. M., Arrese, M. A., Cusi, K. J., Arias, M., Brůha, R., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000542 · Cited by 97
Luukkonen, P. K., Porthan, K., Ahlholm, N., Rosqvist, F., Dufour, S., Zhang, X.-M., Lehtimäki, T. E., Seppänen, W., Orho-Melander, M., Hodson, L., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.008 · Cited by 97
Self-citationGawrieh, S., Vilar-Gomez, E., Wilson, L. A., Pike, F., Kleiner, D. E., Neuschwander-Tetri, B. A., Diehl, A. M., Dasarathy, S., Kowdley, K. V., Hameed, B., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.008 · Cited by 94
Self-citationPulaski, H., Harrison, S. A., Mehta, S. S., Sanyal, A. J., Vitali, M. C., Manigat, L. C., Hou, H., Christudoss, S. P. M., Hoffman, S. M., Stanford-Moore, S. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03301-2 · Cited by 94
Self-citationA global action agenda for turning the tide on fatty liver disease
Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Alazawi, W., Alkhouri, N., Alqahtani, S. A., Anstee, Q. M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000545 · Cited by 93
Self-citationGenetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
Sookoian, S. C., Rotman, Y., & Valenti, L. V. C. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.052 · Cited by 93
Wester, A., Shang, Y., Grip, E. T., Matthews, A., & Hagström, H. (2024) · Gut · doi:10.1136/gutjnl-2023-330962 · Cited by 91
Stine, J. G., Long, M. T., Corey, K. E., Sallis, R. E., Allen, A. M., Armstrong, M. J., Conroy, D. E., Cuthbertson, D. J., Duarte-Rojo, A., Hallsworth, K., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000108 · Cited by 89
Self-citationDillon, J. F., Miller, M. H., Robinson, E. M., Hapca, A., Rezaeihemami, M., Weatherburn, C., McIntyre, P. G., Bartlett, B., Donnan, P. T., Boyd, K. A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.05.033 · Cited by 87
Rising global burden of cancer attributable to high BMI from 2010 to 2019
Tan, D. J. H., Ng, C. H., Muthiah, M. D., Yong, J. N., Chee, D., Teng, M. L. P., Wong, Z. Y., Zeng, R. W., Chin, Y. H., Wang, J., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155744 · Cited by 87
Self-citationJirapinyo, P., McCarty, T. R., Dolan, R. D., Shah, R., & Thompson, C. C. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.017 · Cited by 86 · cited 1×
“Endoscopic bariatric therapies have been developed as an alternative to bariatric surgery and are associated with improvements in histology, liver enzymes and insulin resistance, but more definitive data are required 256,257 .”
Exome-wide association study of plasma lipids in > 300,000 individuals
Liu, D. J., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., Mahajan, A., Saleheen, D., Emdin, C. A., Alam, D. S., Alves, A. C., et al. (2017) · Figshare · Cited by 82
Ng, C. H., Huang, D. Q., & Nguyen, M. H. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0070 · Cited by 82
Self-citationKim, Y., Chang, Y., Cho, Y. K., Ahn, J., Shin, H., & Ryu, S. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.07.006 · Cited by 79
Elsaid, M. I., Li, N., Firkins, S. A., Rustgi, V. K., Paskett, E. D., Acharya, C., Reddy, K. R., Chiang, C. W., & Mumtaz, K. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17925 · Cited by 77
Vilar-Gomez, E., Lou, Z., Kong, N., Vuppalanchi, R., Imperiale, T. F., & Chalasani, N. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.017 · Cited by 75
Effects of vitamin E on stroke: a systematic review with meta-analysis and trial sequential analysis
Loh, H. C., Lim, R., Lee, K. W., Ooi, C. Y., Chuan, D. R., Looi, I., Hay, Y. K., & Khan, N. A. K. (2020) · Stroke and Vascular Neurology · doi:10.1136/svn-2020-000519 · Cited by 75
Malespin, M. H., Barritt, A. S., Watkins, S. E., Schoen, C., Tincopa, M. A., Corbin, K. D., Mospan, A. R., Munoz, B., Trinh, H. N., Weiss, L. M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.01.023 · Cited by 75 · cited 1×
“Despite the clear benefits of weight loss, only a third of patients achieve a ≥5% weight loss and a quarter or even less maintained it 235 .”
Self-citationGlucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes
Yen, F.-S., Hou, M.-C., Cheng-Chung Wei, J., Shih, Y.-H., Hsu, C. Y., Hsu, C.-C., & Hwu, C.-M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.06.004 · Cited by 73
Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes
Björkström, K., Franzén, S., Eliasson, B., Miftaraj, M., Gudbjörnsdottir, S., Trolle-Lagerros, Y., Svensson, A.-M., & Hagström, H. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.04.038 · Cited by 73
Rational combination therapy for NASH: Insights from clinical trials and error
Ratziu, V., & Charlton, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.12.025 · Cited by 71 · cited 1×
“…lipid and glucose metabolism and inflammation 307,308 Given the largely modest proportion of treatment responders in phase III trials of MASH, combining therapies that target distinct metabolic aspects may increase the proportion of responders, the magnitude of response and limit side effects 309 .”
The times they are a-changin' (for NAFLD as well)
Ratziu, V., Rinella, M. E., Beuers, U. H., Loomba, R. S., Anstee, Q. M., Harrison, S. A., Francque, S., Sanyal, A. J., Newsome, P. N., & Younossi, Z. M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.028 · Cited by 70
Self-citationWhat Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review
Talens, M., Tumas, N., Lazarus, J. V., Benach, J., & Pericàs, J. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215019 · Cited by 70
Self-citationWang, Y., Hong, S., Hudson, H., Kory, N., Kinch, L. N., Kozlitina, J., Cohen, J. C., & Hobbs, H. H. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.048 · Cited by 70
Tamaki, N., Ahlholm, N., Luukkonen, P. K., Porthan, K., Sharpton, S. R., Ajmera, V., Kono, Y., Dave, S., Ahmed, A., Sundaram, V., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci162513 · Cited by 69
Baker, C. J., Martinez‐Huenchullan, S. F., D'Souza, M., Xu, Y., Li, M., Bi, Y., Johnson, N. A., & Twigg, S. M. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13086 · Cited by 69
Clinical Indications, Utilization, and Funding of Bariatric Surgery in Europe
Borisenko, O., Colpan, Z., Dillemans, B., Funch-Jensen, P. M., Hedenbro, J., & Ahmed, A. R. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1537-y · Cited by 69
Paik, J. M., Duong, S., Zelber‐Sagi, S., Lazarus, J. V., Henry, L. L., & Younossi, Z. M. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002749 · Cited by 68
Self-citationTapper, E. B., & Lai, M. (2016) · Hepatology · doi:10.1002/hep.28416 · Cited by 67
Stine, J. G., Schreibman, I. R., Faust, A. J., Dahmus, J., Stern, B., Soriano, C., Rivas, G., Hummer, B., Kimball, S. R., Geyer, N. R., et al. (2022) · Hepatology · doi:10.1002/hep.32274 · Cited by 65 · cited 2×
“Physical activity is associated with an improved cholesterol profile, reduction in hepatic and adipose fat, improvements in liver enzymes and a decreased thrombotic risk in people with MASLD, and these benefits may occur independent of weight loss 240,241 .”
Self-citationEbrahimi, F., Hagström, H., Sun, J., Bergman, D., Shang, Y., Yang, W., Roelstraete, B., & Ludvigsson, J. F. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.08.018 · Cited by 65 · cited 1×
“A nationwide multigen-erational cohort study of family members of Swedish adults with biopsy-proven MASLD determined that first-degree relatives had a higher risk of liver-related outcomes and HCC than matched controls from the general population 111 .”
Tavaglione, F., Amangurbanova, M., Yang, A. H., Tincopa, M. A., Ajmera, V. H., Richards, L., Butcher, C., Hernandez, C., Madamba, E. V., Singh, S., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18506 · Cited by 65
Self-citationRobertis, R. D., Spoto, F., Autelitano, D., Guagenti, D., Olivieri, A. M., Zanutto, P., Incarbone, G., & D’Onofrio, M. (2023) · La radiologia medica · doi:10.1007/s11547-023-01693-8 · Cited by 64
Goh, G. B.-B., Chow, W.-C., Wang, R., Yuan, J.-M., & Koh, W.-P. (2014) · Hepatology · doi:10.1002/hep.27054 · Cited by 63
Yang, A. H., Tincopa, M. A., Tavaglione, F., Ajmera, V. H., Richards, L., Amangurbanova, M., Butcher, C. H., Hernandez, C., Madamba, E. V., Singh, S., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332917 · Cited by 63
Self-citationGidener, T., Dierkhising, R. A., Mara, K. C., Therneau, T. M., Venkatesh, S. K., Ehman, R. L., Yin, M., & Allen, A. M. (2023) · Hepatology · doi:10.1002/hep.32594 · Cited by 62 · cited 1×
“Similarly, a study of 128 participants with MASLD and serial MREs determined that a change of ≥19% in liver stiffness measurement by MRE was associated with decompensation or death 208 .”
Uzoigwe, C., Liang, Y., Whitmire, S., & Paprocki, Y. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01053-7 · Cited by 62
Younossi, Z. M., Stepanova, M., Lawitz, E., Reddy, K. R., Wong, V. W., Mangia, A., Muir, A. J., Jacobson, I. M., Djedjos, C. S., Gaggar, A., et al. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000375 · Cited by 60
Self-citationOpportunities and challenges following approval of resmetirom for MASH liver disease
Lazarus, J. V., Ivancovsky Wajcman, D., Mark, H. E., Younossi, Z. M., Kopka, C. J., Cohen, N., Bansal, M. B., Betel, M., & Brennan, P. N. (2024) · Nature Medicine · doi:10.1038/s41591-024-02958-z · Cited by 60 · cited 1×
“After years of failed trials, in 2024 the US FDA approved resmetirom, a THRβ agonist, for the treatment of MASH 17 .”
Self-citationAmangurbanova, M., Huang, D. Q., & Loomba, R. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17292 · Cited by 59
Self-citationZhang, X., Wong, G. L., Yip, T. C., Cheung, J. T. K., Tse, Y., Hui, V. W., Lin, H., Lai, J. C., Chan, H. L., Kong, A. P., et al. (2022) · Hepatology · doi:10.1002/hep.32476 · Cited by 56
Self-citationLazarus, J. V., Castéra, L., Mark, H. E., Allen, A. M., Adams, L. A., Anstee, Q. M., Arrese, M. A., Alqahtani, S. A., Bugianesi, E., Colombo, M., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100596 · Cited by 56
Self-citationNASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
Koh, J. H., Ng, C. H., Nah, B. K. Y., Tan, D. J. H., Loomba, R. S., Huang, D. Q., Lim, W. H., Xiao, J., Fu, C., Zeng, R. W., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.05.019 · Cited by 56
Self-citationZhang, X., Yip, T. C.-F., Wong, G. L.-H., Leow, W.-X., Liang, L. Y., Lim, L.-L., Li, G., Ibrahim, L., Lin, H., Lai, J. C. T., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330269 · Cited by 55 · cited 1×
“Implementing a consistent clinical care pathway in the community may be challenging, but automated fibrosis score calculation in at-risk populations may mitigate some of the difficulties in identifying individuals at high risk of advanced fibrosis 220 .”
Self-citationGuillaume, M., Moal, V., Delabaudiere, C., Zuberbuhler, F., Robic, M., Lannes, A., Metivier, S., Oberti, F., Gourdy, P., Fouchard‐Hubert, I., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15529 · Cited by 55
Self-citationHuang, D. Q., Fowler, K. J., Liau, J., Cunha, G. M., Louie, A. L., An, J. Y., Bettencourt, R., Jung, J., Gitto, Z., Hernandez, C., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16844 · Cited by 55
Self-citationHuang, D. Q., Sharpton, S. R., Amangurbanova, M., Tamaki, N., Sirlin, C. B., Loomba, R. S., Bettencourt, R., Madamba, E. V., Jung, J., Siddiqi, H., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.08.036 · Cited by 54
Self-citationEngström, A., Wintzell, V., Melbye, M., Svanström, H., Eliasson, B., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Hviid, A., Ueda, P., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000712 · Cited by 54
Younossi, Z. M., Alqahtani, S. A., Funuyet‐Salas, J., Romero‐Gómez, M., Yilmaz, Y. N., Keklikkıran, Ç., Alswat, K., Yu, M., Liu, C., Fan, J., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101066 · Cited by 53
Self-citationCastera, L., Garteiser, P., Laouenan, C., Vidal-Trécan, T., Vallet-Pichard, A., Manchon, P., Paradis, V., Czernichow, S., Roulot, D., Larger, E., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.03.023 · Cited by 53
A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD
Calès, P., Canivet, C. M., Costentin, C. E., Lannes, A., Oberti, F., Fouchard, I., Hunault, G., de Lédinghen, V., & Boursier, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.11.049 · Cited by 53
Self-citationYounossi, Z. M., Wong, V. W., Anstee, Q. M., Romero‐Gomez, M., Trauner, M. H., Harrison, S. A., Lawitz, E. J., Okanoue, T., Camargo, M., Kersey, K., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1581 · Cited by 52
Self-citationCanivet, C. M., Costentin, C., Irvine, K. M., Delamarre, A., Lannes, A., Sturm, N., Oberti, F., Patel, P. J., Decaens, T., Irles‐Depé, M., et al. (2023) · Hepatology · doi:10.1002/hep.32665 · Cited by 49
Self-citationEnhanced liver Fibrosis® test predicts liver-related outcomes in the general population
Saarinen, K., Färkkilä, M. A., Jula, A., Erlund, I., Vihervaara, T., Lundqvist, A., & Åberg, F. O. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100765 · Cited by 49
Vitamin E Intake and Risk of Prostate Cancer: A Meta-Analysis
Loh, W. Q., Youn, J., & Seow, W. J. (2022) · Nutrients · doi:10.3390/nu15010014 · Cited by 48
MASH clinical trials and drugs pipeline: An impending tsunami
Noureddin, M. (2025) · Hepatology · doi:10.1097/hep.0000000000000860 · Cited by 48
Pai, R. K., Kleiner, D. E., Hart, J., Adeyi, O. A., Clouston, A. D., Behling, C. A., Jain, D., Kakar, S., Brahmania, M., Burgart, L., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15503 · Cited by 47
Self-citationShared Mechanisms between Cardiovascular Disease and NAFLD
Huang, D. Q., Downes, M., Evans, R. M., Witztum, J. L., Glass, C. K., & Loomba, R. S. (2022) · Seminars in Liver Disease · doi:10.1055/a-1930-6658 · Cited by 47
Self-citationSurveillance of the liver in type 2 diabetes: important but unfeasible?
Qadri, S. U., & Yki‐Järvinen, H. (2024) · Diabetologia · doi:10.1007/s00125-024-06087-7 · Cited by 47
Self-citationYounossi, Z. M., Stepanova, M., Racila, A., Henry, L. L., Labriola, D., Taub, R. A., & Nader, F. (2024) · Hepatology · doi:10.1097/hep.0000000000001084 · Cited by 47
Ratziu, V., Harrison, S. A., Hajji, Y., Magnanensi, J., Petit, S., Majd, Z., Delecroix, E., Rosenquist, C., Hum, D. W., Staels, B., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.10.038 · Cited by 45
Loomba, R., Amangurbanova, M., Bettencourt, R., Madamba, E., Siddiqi, H., Richards, L., Behling, C., Sirlin, C. B., Gottwald, M. D., Feng, S., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331401 · Cited by 43 · cited 1×
“…led to the development of a novel index, the MASH Resolution Index, comprising MRI–PDFF, ALT and aspartate transaminase, which outperformed absolute changes in MRI–PDFF and ALT, and had an AUC of 0.83 for identifying MASH resolution without worsening fibrosis in an external validation cohort 217 .”
InfluentialSelf-citationPNPLA3 Genotype and Risk of Liver and All‐Cause Mortality
Stender, S., & Loomba, R. (2020) · Hepatology · doi:10.1002/hep.31113 · Cited by 43
Self-citationAgile scores in MASLD and ALD: External validation and their utility in clinical algorithms
Papatheodoridi, Μ., de Lédinghen, V., Lupșor‐Platon, M., Bronte, F., Boursier, J., Elshaarawy, O., Marra, F., Thiele, M. S., Markakis, G., Payancé, A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.021 · Cited by 43
Self-citationHuang, D. Q., Wilson, L., Behling, C. A., Amangurbanova, M., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001015 · Cited by 42
Self-citationSamala, N. R., Desai, A. P., Gómez, E. V., Smith, E. R., Gawrieh, S., Kettler, C. D., Pike, F., & Chalasani, N. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.046 · Cited by 36
Wai-Sun Wong, V., Anstee, Q. M., Nitze, L. M., Geerts, A., George, J., Nolasco, V., Kjær, M. S., Ladelund, S., Newsome, P. N., & Ratziu, V. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102310 · Cited by 36
Truong, E., GORNBEIN, J. A., Yang, J. D., Noureddin, N., Harrison, S. A., Alkhouri, N., & Noureddin, M. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.02.003 · Cited by 35
Sheikh, I. M., Hassan, O. A., Adam, S. M., Ali, A. I., Ogedegbe, O. J., Tabowei, G., Barbarawi, A., Yussuf, F. M., & Nor, M. A. (2023) · Cureus · doi:10.7759/cureus.46911 · Cited by 35
Eslam, M., Chen, F., & George, J. (2020) · Clinical Liver Disease · doi:10.1002/cld.930 · Cited by 33
Noninvasive assessment of hepatic decompensation
Thiele, M. S., Johansen, S., Israelsen, M. E., Trebicka, J., Abraldeṣ, J. G., Ginès, P., & Krag, A. A. (2023) · Hepatology · doi:10.1097/hep.0000000000000618 · Cited by 33
Canivet, C. M., Zheng, M., Qadri, S. U., Vonghia, L., Chuah, K. H., Costentin, C. E., George, J., Armandi, A., Adams, L. A., Lange, N. F., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.03.032 · Cited by 32
Self-citationIntegrating social nutrition principles into the treatment of steatotic liver disease
Wajcman, D. I., Brennan, P., Kopka, C. J., Zelber‐Sagi, S., Younossi, Z. M., Allen, A. M., Flórez, K. R., & Lazarus, J. V. (2023) · Communications Medicine · doi:10.1038/s43856-023-00398-3 · Cited by 31
Self-citationPapatheodoridi, Μ., Pallini, G., Aithal, G. P., Lim, H. K., Cobbold, J., Torres, M. C. P., Misas, M. G., Ryan, J. D., Tomlinson, J., Allison, M. E., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.04.018 · Cited by 30
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
Roskilly, A., Hicks, A., Taylor, E., Jones, R. L., Parker, R., & Rowe, I. A. C. (2020) · Liver International · doi:10.1111/liv.14749 · Cited by 29
Noureddin, N., Ajmera, V. H., Bergstrom, J., Bettencourt, R., Huang, D. Q., Siddiqi, H., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17707 · Cited by 28
Self-citationNonalcohol fatty liver disease: balancing supply and utilization of triglycerides
Santos‐Báez, L. S., & Ginsberg, H. N. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000756 · Cited by 26
Park, H., Yoon, E. L., Kim, M., Kwon, S., Kim, D., Cheung, R. C., Kim, H., & Jun, D. W. (2024) · Liver International · doi:10.1111/liv.15838 · Cited by 26
Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
Tan, D. J. H., Tamaki, N., Kim, B. K., Wijarnpreecha, K., Aboona, M. B., Faulkner, C., Kench, C., Salimi, S., Sabih, A., Lim, W. H., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.18346 · Cited by 26
Self-citationMoret, A., Boursier, J., Houssel‐Debry, P., Riou, J., Crouan, A., Dubois, M., Provost, S. M., Aubé, C., & Paisant, A. (2020) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-1233-2290 · Cited by 25
Self-citationPaik, A., Henry, L. L., de Avila, L., Alqahtani, S. A., Nader, F., Paik, J. M., & Younossi, Z. M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.08.053 · Cited by 25
Brennan, P., Kopka, C. J., Agirre‐Garrido, L., Hansen, C. D., Alkhouri, N., Schattenberg, J. M., Wajcman, D. I., Isaacs, S. D., Michel, M. S., & Lazarus, J. V. (2025) · npj gut and liver. · doi:10.1038/s44355-024-00017-5 · Cited by 25
Self-citationNg, C. H., Lim, W. H., Chin, Y. H., Yong, J. N., Zeng, R. W., Chan, K. E., Tan, D. J. H., Fu, C. E., Tang, A. S. P., Goh, L. H., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17121 · Cited by 24
Self-citationSanchez, L. O., Zhan, C.-Y., Cauduro, C. G. D. S., Crenier, L., Njimi, H., Englebert, G., Putignano, A., Lepida, A., Degré, D., Boon, N., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100791 · Cited by 21
Increased risk for microvascular outcomes in NAFLD—A nationwide, population‐based cohort study
Ebert, T., Widman, L., Stenvinkel, P., & Hagström, H. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13673 · Cited by 21
Kim, B. K., Bernstein, N., Huang, D. Q., Tamaki, N., Imajo, K., Yoneda, M., Sutter, N., Jung, J., Nguyen, K., Nguyen, L., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17564 · Cited by 20
Self-citationBoursier, J., Roux, M., Costentin, C. E., Chaigneau, J., Fournier, C., Trylesinski, A., Canivet, C. M., Michalak, S., Bail, B. L., Paradis, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40328-4 · Cited by 19
Self-citationSebastiani, G., Milić, J., Kablawi, D., Gioè, C., Hinai, A. S. A., Lebouché, B., Tsochatzis, E. A., Finkel, J., Ballesteros, L. R., Ramanakumar, A. V., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad203 · Cited by 16
A turning point in hepatology? EASL reflects on the first approved drug for MASH
Francque, S., Krag, A. A., Shawcross, D. L., & Zelber‐Sagi, S. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.036 · Cited by 16
Huang, D. Q., Ahlholm, N., Luukkonen, P. K., Porthan, K., Amangurbanova, M., Madamba, E. V., Bettencourt, R., Siddiqi, H., Cervantes, V., Hernandez, C., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.06.020 · Cited by 14
Self-citationHeerkens, L., van Kleef, L. A., de Knegt, R. J., Voortman, T., & Geleijnse, J. M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287467 · Cited by 13
Lim, W. H., Lin, S. Y., Ng, C. H., Tan, D. J. H., Xiao, J., Yong, J. N., Tay, P. W. L., Syn, N. L. X., Chin, Y. H., Chan, K. E., et al. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-520 · Cited by 11
Self-citationHuang, D. Q., Tran, S., Barnett, S. D., Zou, B., Yeo, Y. H., Cheung, R. C., & Nguyen, M. H. (2023) · Hepatology International · doi:10.1007/s12072-023-10616-8 · Cited by 11
Self-citationPatient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease
Barberá, A., White, T. M., Arora, A. K., Henry, L. L., Lazarus, J. V., & Younossi, Z. M. (2024) · Seminars in Liver Disease · doi:10.1055/a-2435-2091 · Cited by 11
Self-citationNoureddin, N., Huang, D. Q., Bettencourt, R., Siddiqi, H., Majzoub, A. M., Nayfeh, T., Tamaki, N., Izumi, N., Nakajima, A., Idılman, R., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17981 · Cited by 10
Self-citationZhang, X., Yip, T. C., Wong, G. L., Leow, W.-X., Liang, Y., Lim, L., Li, G., Ibrahim, L., Lin, H., Lai, C. T., et al. (2023) · Journal of Hepatology · doi:10.1016/s0168-8278(23)00482-8 · Cited by 8
Self-citation
Cited by
Metabolic Dysfunction–Associated Steatotic Liver Disease in Adults: A Review
Tilg, H., Petta, S., Stefan, N., & Targher, G. (2026) · JAMA · doi:10.1001/jama.2025.19615 · Cited by 221
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Self-citationLoomba, R., Daniel, P. C.-Y. N., Amangurbanova, M., Bettencourt, R., Madamba, E., Siddiqi, H., Richards, L., Gottwald, M. D., Feng, S., Margalit, M., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001396 · Cited by 17
Self-citationRegulatory T cells safeguard liver health during metabolic-associated steatohepatitis
Hanna, B. S., Langston, P. K., Marin-Rodero, M., Ramirez, R. N., Wan, M., Benoist, C., & Mathis, D. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536314123 · Cited by 1
“M etabolic - dysfunction - a ssociated s teatoh epatitis (MASH) is a related but distinct inflammatory complication of the metabolic syndrome, characterized by steatosis, hepatocellular injury, immunocyte accumulation, and progressive fibrosis (11).”
Metadata
- Authors
- Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R.
- Venue
- Nature Reviews Disease Primers
- Published
- 2025-03-06
- Volume
- 11
- Issue
- 1
- Pages
- 14-14
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4408204932
- Cited by
- 293
- References
- 355
- FWCI
- 73.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.